Study record managers: refer to the Data Element Definitions if submitting registration or results information.
|1||NCT02819518||Recruiting||Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)||
||858||All||18 Years and older (Adult, Senior)||NCT02819518||3475-355
|July 27, 2016||December 30, 2019||December 30, 2019||June 30, 2016||February 14, 2018||